Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD
暂无分享,去创建一个
F Träber | E Keller | R Lamerichs | F. Jessen | H. Schild | A. Papassotiropoulos | R. Lamerichs | S. Flacke | R. Heun | F. Träber | W. Block | E. Keller | F Jessen | A Papassotiropoulos | R Heun | H H Schild | S Flacke | W Block | F. Jessen | H. Schild
[1] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[2] K O Lim,et al. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. , 1999, Archives of general psychiatry.
[3] J. Saunders,et al. Double inversion recovery improves water suppression in vivo , 1993, Magnetic resonance in medicine.
[4] G. Fein,et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging , 1994, Annals of neurology.
[5] B R Rosen,et al. 1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.
[6] P. Jolles,et al. Regional metabolic alterations in Alzheimer's disease: an in vitro 1H NMR study of the hippocampus and cerebellum. , 1997, The journals of gerontology. Series A, Biological sciences and medical sciences.
[7] D J Jenden,et al. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. , 1996, Life sciences.
[8] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[9] R. Kreis,et al. Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus: detection with proton MR spectroscopy. , 1992, Radiology.
[10] J. Coyle,et al. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. , 1997, Molecular and chemical neuropathology.
[11] P. Bottomley. Spatial Localization in NMR Spectroscopy in Vivo , 1987, Annals of the New York Academy of Sciences.
[12] O. Henriksen,et al. Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease. , 1995, Magnetic resonance imaging.
[13] M Noble,et al. Specific Expression of N‐Acetylaspartate in Neurons, Oligodendrocyte‐Type‐2 Astrocyte Progenitors, and Immature Oligodendrocytes In Vitro , 1992, Journal of neurochemistry.
[14] D. Arnold,et al. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo , 1994, Neurology.
[15] J. Gawehn,et al. PROTON MAGNETIC RESONANCE SPECTROSCOPY IN DEMENTIA OF ALZHEIMER TYPE , 1997, International journal of geriatric psychiatry.
[16] G. Fein,et al. Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.
[17] G. Fein,et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease , 1997, Neurology.
[18] T. Ernst,et al. Abnormal cerebral metabolite concentrations in patients with probable alzheimer disease , 1994, Magnetic resonance in medicine.
[19] P A Narayana,et al. In vivo proton magnetic resonance spectroscopy studies of human brain. , 1991, Magnetic resonance imaging.
[20] F Träber,et al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. , 1998, Archives of neurology.
[21] G. Fein,et al. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. , 1996, Archives of neurology.
[22] G. Fein,et al. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. , 1998, Radiology.
[23] H. Möller,et al. [1H-MR spectroscopic imaging in patients with clinically diagnosed Alzheimer's disease]. , 1995, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.
[24] T Ernst,et al. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. , 1997, Radiology.
[25] I. Wilkinson,et al. Localized cerebral proton MR spectroscopy in HIV infection and AIDS. , 1994, AJNR. American journal of neuroradiology.
[26] W. Brooks,et al. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. , 1996, Archives of neurology.
[27] B D Ross,et al. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. , 1992, Radiology.
[28] Barbara Palumbo,et al. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging , 1997, Mechanisms of Ageing and Development.
[29] Pradeep Rajagopalan,et al. Nuclear magnetic resonance spectroscopy: A review of neuropsychiatric applications , 1995, Progress in Neuro-psychopharmacology and Biological Psychiatry.
[30] D M Doddrell,et al. A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. , 1999, Magnetic resonance imaging.
[31] K. Krishnan,et al. Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy , 1998, Psychiatry Research: Neuroimaging.
[32] B D Ross,et al. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. , 1993, Radiology.
[33] B D Ross,et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. , 1995, Radiology.
[34] N. Lundbom,et al. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging , 1996, Neurology.
[35] B. Miller. A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline , 1991, NMR in biomedicine.